THE MANAGEMENT OF REFRACTORY DISTAL COLITIS

1 Irvine EJ. Assessing outcome in randomized clinical trials: inflammatory bowel disease. Can J Gastroenterol 1993; 7:561-7.

2 Jarnerot G JE Lennard-Jones Bianchi-Porro G Medical treatment of refractory distal ulcerative colitis. Gastroenterol Int 1991; 4:93-8.

3 Travis SPL E Dannatt McGovern DPB Managed care for distal ulcerative colitis: preliminary results. Gut 2001; 48(Suppl):A87.

4 Farup PG O Hovde Halvorsen FA Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol 1995; 30:164-70.

5 Van Bodegraven AA RO Boer Lourens J Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 1996; 10:327-32.

6 Marshall JK Irvine EJ. Rectal corticosteroids versus alternative treatment in ulcerative colitis: a meta-analysis. Gut 1997; 40:775-81.

7 Honda M F Orii Ayabe T Expression of glucocorticoid receptor b in lymphocytes of patients with glucocorticoidresistant ulcerative colitis. Gastroenterology 2000; 118:819-66.

8 Hearing SD M Norman Probert CSJ Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999; 45:382-8.

9 Sninsky CA DH Cort Shanahan F Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicentre study. Ann Intern Med 1990; 115:350-5.

10 Sutherland LR DE Roth Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3:65-78.

11 Truelove SC G Watkinson Draper G. Comparison of corticosteroid and SASP therapy in ulcerative colitis. BMJ 1962; 2:1708-11.

12 Lennard-Jones JE AJ Longmore Newell AC An assessment of prednisone, Salazopyrin and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960; 1:217-22.

13 Baron JH AM Connell Kanaghinis TG Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. BMJ 1962; 2:441-3.

14 Marshall JK Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9:293-300.

15 Lee FI DP Jewell Mani V A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 1996; 38:229-33.

16 Campieri M P Gionchetti Belluzzi A Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991; 32:929-31.

17 Mulder CJJ P Fockens Meijer JWR Beclomethasone dipropionate (3mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3mg/2g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996; 8:549-53.

18 Gionchetti P F Rissole Ventura A Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther 1997; 11:1053-7.

19 Rao SSC NW Read Brown C Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology 1987; 93:934-40.

20 Allison MC Vallance R. Prevalence of proximal faecal stasis in active ulcerative colitis. Gut 1991; 32:179-82.

21 Travis SPL JM Farrant Ricketts C Predicting outcome in severe ulcerative colitis. Gut 1996; 38:905-10.

22 Jarnerot G P Rolny Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89:1005-13.

23 Hyde GM A Thillainayagam Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998; 10:411-13.

24 Ayres RC CD Gillen Walmsley RS Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol 1996; 8:555-8.

25 Christensen LA J Fallingborg Jacobsen BA Comparative bioavailability of 5-aminosalicylic acid from controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 1994; 8:289-94.

26 Travis SPL C Tysk de Silva HJ Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994; 35:1282-6.

27 Courtney M D Nunes Bergin C Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992; 339:1279-81.

28 Green JRB JA Gibson Kerr GD Maintenance treatment with balsalazide provides more effective control of nocturnal symptoms of ulcerative colitis than delayed-release mesalazine. Gastroenterology 1998; 114:A987.

29 Scholmerich J. Immunosuppressive treatment for refractory ulcerative colitis – where do we stand and where are we going? Eur J Gastroenterol Hepatol 1997; 9:842-9.

30 Hawthorne AB RFA Logan Hawkey CJ Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305:20-2.

31 Fraser AG Jewell DP. Relapse rates on and after stopping azathioprine treatment for inflammatory bowel disease. Gastroenterology 2000; 118:A816-17.

32 McGovern DPB M Shobowale-Bakre Duly J Azathioprine intolerance is independent of thiopurine methyl transferase activity. Gastroenterology 2000; 118:A890.

33 Marteau P J Crand Foucault M Use of mesalazine slowrelease suppositories 1g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998, 42:195-9.

34 Ardizzone S Bianchi Porro G. A practical guide to the management of distal ulcerative colitis. Drugs 1998; 55: 519-42.

35 Saibil FG. Lidocaine enemas for intractable distal ulcerative colitis: efficacy and safety. Gastroenterology 1998; 114:A1073.

36 Forbes A TC Britton House IM Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther 1989; 3:553-6.

37 Pullan RD S Ganesh Mani V Comparison of bismuth citrate and 5-aminosalicylic acid enemas in active distal ulcerative colitis: a controlled trial. Gut 1993; 34:676-9.

38 Sandborn WJ WJ Tremaine Schroeder KW A placebocontrolled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994; 106:1429-35.

39 Jarlov AE P Munkholm Schmidt PN Treatment of active distal ulcerative colitis with immunoglobulin G enemas. Aliment Pharmacol Ther 1993; 7:561-5.

40 Schreiber S T Heinig Thiele HG Immunoregulatory role of interleukin-10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108:1434-44.

41 Pullan RD J Rhodes Ganesh S Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330:811-95.

42 Thomas GAO J Rhodes Ragunath K Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8:769-76.

43 Green JT GAO Thomas Rhodes J Nicotine enemas for active ulcerative colitis – a pilot study. Aliment Pharmacol Ther 1997; 11:859-63.

44 Patz J WZ Jacobsohn Gottschalk-Sabag S Treatment of refractory distal colitis with short-chain fatty acid enemas. Am J Gastroenterol 1996; 91:731-4.

45 Breuer RI KH Soergel Lashner BA Short-chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomized, placebo-controlled trial. Gut 1997; 40:485-91.

46 Campieri M P Gionchetti Belluzzi A Sucralfate, 5- aminosalicylic acid and placebo enemas in the treatment of distal ulcerative colitis. Eur J Gastroenterol &Hepatol 1991; 3:41-4.

47 Van Outryve M F Huble Van Eeghem P Comparison of Ridrogel versus prednisolone, both administered rectally, for the treatment of active ulcerative colitis. Gastroenterology 1996; 110:A1035.

48 Langholz E P Munkholm Davidsen M Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994, 107:3-11.

49 Brunel M C Penne Tiret E Restorative proctocolectomy for distal ulcerative colitis. Gut 1999; 45:542-5.